IFNGR2 and breast cancer: Our data suggest that several pathway members, such as Stat1, Ifngr2, Tgtp1, Ifit1, Gbp1 and Gbp3, may be suitable biomarkers for residual disease in breast cancer patients treated with cytotoxic chemotherapy.